Template:Neisseria meningitis post exposure prophylaxis: Difference between revisions
| Line 17: | Line 17: | ||
**Adult: 500 mg, po x 1 | **Adult: 500 mg, po x 1 | ||
*[[Ciprofloxacin]] 500mg PO x1 | *[[Ciprofloxacin]] 500mg PO x1 | ||
**No longer recommended as an option in California | **No longer recommended as an option in California<ref>https://www.cdph.ca.gov/Programs/OPA/Pages/CAHAN/ca-discontinuation-of-ciprofloxacin-for-invasive-meningococcal-disease-pep.aspx</ref> | ||
**Do not use in patients with recent travel to Saudi Arabia<ref>https://www.cdc.gov/mmwr/volumes/73/wr/mm7322e1.htm</ref> | **Do not use in patients with recent travel to Saudi Arabia<ref>https://www.cdc.gov/mmwr/volumes/73/wr/mm7322e1.htm</ref> | ||
Latest revision as of 15:57, 6 November 2024
Only for meningococcus exposure
Indications
- Household contacts
- School or day care contacts in previous 7 days
- Direct exposure to patient's secretions (kissing, shared utensils or toothbrush)
- Intubation without facemark
Prophylaxis regimen
Either of the options are acceptable
- Rifampin 600mg PO BID x2d
- 5mg/kg PO if < 1 month old
- 10mg/kg PO ≥ 1 month old
- Ceftriaxone 250mg IM x1
- 125mg IM if ≤ 15 years old
- Ceftriaxone should be used for pregnant patients
- Azithromycin[1]
- Pediatric: 10 mg/kg (maximum 500 mg), po x 1
- Adult: 500 mg, po x 1
- Ciprofloxacin 500mg PO x1
- ↑ https://www.cdph.ca.gov/Programs/OPA/Pages/CAHAN/ca-discontinuation-of-ciprofloxacin-for-invasive-meningococcal-disease-pep.aspx
- ↑ https://www.cdph.ca.gov/Programs/OPA/Pages/CAHAN/ca-discontinuation-of-ciprofloxacin-for-invasive-meningococcal-disease-pep.aspx
- ↑ https://www.cdc.gov/mmwr/volumes/73/wr/mm7322e1.htm